



Omar Hasan Ali

Contact

Omar Hasan Ali

Units

Medizinisches Forschungszentrum

Publications (15)

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. *Sci Immunol* 2022; 7:eabn9644.

Garreta E, Prado P, Stanifer M, Monteil V, Marco A, Ullate-Agote A, Moya-Rull D, Vilas-Zornoza A, Tarantino C, Romero J, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo Cantaño M, González F, Domingo-Pedrol P, Gavaldà A, Del Pozo C, Hasan Ali O, Ventura-Aguilar P, Campistol J, Prosper F, Mirazimi A, Boulant S, Penninger J, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. *Cell Metab* 2022; 34:857-873.e9.

Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. *J Cancer Res Clin Oncol* 2021; 148:647-656.

Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludwig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. *Oncoimmunology* 2021; 10:2006893.

Hasan Ali O, Bomze D, Risch L, Brugger S, Paprotny M, Weber M, Thiel S, Kern L, Albrich W, Kohler P, Kahlert C, Vernazza P, Bühler P, Schüpbach R, Gómez-Mejía A, Popa A, Bergthaler A, Penninger J, Flatz L. Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:1746.

Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejía A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:e2869-e2874.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2019; 82:854-861.

Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol* 2019

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludwig B, Levesque M, Dummer R, Siano M, Krolík M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Hasan Ali O, Lenz T, Driessen C, Früh M, Jörgen M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. *Eur J Cancer* 2018; 107:8-14.

Betschart P, Zumstein V, Hasan Ali O, Schmid H, Abt D. Readability Assessment of Patient Education Material Published by German-Speaking Associations of Urology. *Urol Int* 2017; 100:79-84.

Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. *Cancer Immunol Immunother* 2017; 67:39-45.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415-417.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Projects (1)

The role of keratinocyte-differentiation antigens in head and neck squamous cell cancer

Fundamental Research - Nov 1, 2022 - Oct 30, 2025

Ongoing

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch